Merck Orion Ink Collaboration To Develop And Commercialize Investigational Steroid Synthesis Inhibitor ODM-208 To Treat MCRPC
By, Admin1 min read
Share
Merck, known as MSD outside the United States and Canada, and Orion Corporation (Orion) announced a global development and commercialization agreement for Orion
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
